Are sodium‑glucose co‑transporter 2 (SGLT2) inhibitors contraindicated in patients with an ampullary mass?

Are SGLT2 Inhibitors Contraindicated in Patients with Ampullary Mass?

No, SGLT2 inhibitors are not contraindicated in patients with an ampullary mass. There is no evidence in current guidelines or drug labels establishing ampullary masses as a contraindication to SGLT2 inhibitor therapy.

Established Contraindications

Based on the most recent guidelines, the only absolute contraindication for SGLT2 inhibitors is type 1 diabetes 1. The FDA and international guidelines do not list ampullary masses, pancreatic masses, or biliary tract pathology as contraindications.

Key Considerations for Use

Renal Function Requirements

SGLT2 inhibitors can be initiated in patients with:

• eGFR ≥20 mL/min/1.73 m² for cardiovascular and kidney benefits 2, 3
• Once started, they can be continued even as eGFR declines below 20, until dialysis or transplantation 4
• Glucose-lowering efficacy diminishes below eGFR 45 mL/min/1.73 m², but cardiorenal benefits persist 5, 6

Perioperative Management

If the patient with an ampullary mass requires surgery (e.g., Whipple procedure):

• Stop SGLT2 inhibitors 3 days before elective surgery (4 days for ertugliflozin) 7, 8, 9
• This prevents euglycemic diabetic ketoacidosis (euDKA) in the perioperative period 10, 11
• The surgical stress, prolonged fasting, and metabolic changes are the key triggers for ketoacidosis, not the ampullary mass itself 7

Sick Day Management

If the ampullary mass causes:

• Nausea, vomiting, or reduced oral intake: Hold SGLT2 inhibitors temporarily 1, 10
• Dehydration or acute illness: Implement sick-day rules and discontinue until recovery 7, 5

Clinical Reasoning

The concern with ampullary masses relates to potential perioperative complications and metabolic stress, not the mass itself. The risk of euDKA increases when patients:

• Are fasting or have reduced carbohydrate intake
• Are undergoing major surgery
• Have concurrent illness with vomiting or dehydration
• Are receiving insulin therapy 10, 11

The ampullary mass does not independently contraindicate SGLT2 inhibitor use. The decision hinges on:

1. Whether surgery is planned (stop 3-4 days prior)
2. Whether the patient has adequate oral intake
3. Whether renal function meets criteria (eGFR ≥20)
4. Whether the patient has type 1 diabetes (absolute contraindication)

Practical Algorithm

For patients with ampullary mass on SGLT2 inhibitors:

• If asymptomatic and no surgery planned: Continue SGLT2 inhibitor if eGFR ≥20 2, 3
• If symptomatic (nausea, vomiting, anorexia): Hold SGLT2 inhibitor until symptoms resolve 1, 10
• If surgery scheduled: Stop 3 days before procedure (4 days for ertugliflozin) 7, 8
• Postoperatively: Resume only when patient is eating normally, hemodynamically stable, and euvolemic 7, 12

Monitor for signs of ketoacidosis (nausea, vomiting, abdominal pain, dyspnea) even with normal glucose levels, and measure serum ketones if suspected 1, 10.